Phoenix Nirvana Furen pharmaceutical industry opens the curtain of resource integration

[China Pharmaceutical network enterprise news] in recent years, the pharmaceutical industry has developed rapidly However, due to the influence of small scale, single product and other factors, the development of traditional Chinese medicine business has fallen into a bottleneck, and it is difficult to further improve the sales scale and business performance Recently, the company plans to issue shares and pay cash to 14 counterparties, including Furen group, the controlling shareholder, to purchase 100% of the shares of kaiyao group Recently, Furen pharmaceutical announced that the company plans to issue shares and pay cash to 14 counterparties, including the controlling shareholder Furen group, to purchase 100% of the shares of the group, with a transaction price of 7.809 billion yuan At the same time, the restructuring plan disclosed that the company raised no more than 5.3 billion yuan of supporting funds through non-public issuance of shares After the implementation of this restructuring, Furen group is still the controlling shareholder of the listed company Phoenix Nirvana Fu Ren ushers in the second spring In the 1990s, Fu Ren group was born, with the diversity and vitality of the times In a long-term and large-scale situation, since 2001, Furen group has gradually formed a number of wholly-owned and holding subsidiaries, including Henan Furen Tang Pharmaceutical Co., Ltd., Henan Furen Huaiqing Tang Pharmaceutical Co., Ltd., Kaifeng Pharmaceutical (Group) Co., Ltd., Furen Pharmaceutical Group Industrial Co., Ltd., with the initial intention of M & A and scale expansion In 2006, Furen group became the controlling shareholder of Furen pharmaceutical through equity transfer, and injected Furen Tang into Furen pharmaceutical, completing the listing of its proprietary Chinese medicine assets Furen group became the main listed company of Furen pharmaceutical and injected into Furen hall, laying the foundation for the listing of pharmaceutical assets In recent years, the pharmaceutical industry has developed rapidly, but under the influence of small scale, single product and other factors, the development of traditional Chinese medicine business has fallen into a bottleneck, and it is difficult to further improve the sales scale and business performance In 2016, the company's revenue was 496 million yuan, and the net profit attributable to the shareholders of the parent company was 18 million yuan In sharp contrast, after years of development and accumulation, the group has developed into a comprehensive large-scale pharmaceutical enterprise integrating the research and development, production and sales of chemical drugs, Chinese patent medicines and APIs, which is the pharmaceutical operation assets of Furen group At present, there are more than 480 drug approval numbers, including more than 300 varieties selected in the medical insurance catalogue (2017 Edition) As of the end of 2016, its assets amounted to 7.515 billion yuan, about six times the scale of Furen pharmaceutical industry In 2016, the revenue reached 4.534 billion yuan, with a net profit attributable to the parent company of 653 million yuan Therefore, seeking for the injection of assets within the group has become the best choice for Furen pharmaceutical industry to break through the bottleneck and achieve coordinated development It is expected that after the completion of this transaction, the assets scale of listed companies will surge to 9.22 billion yuan, and the large-scale comprehensive pharmaceutical listed company platform built by Furen will soon emerge Innovation ability of warm air frequency blowing is supported In recent years, China's pharmaceutical industry has witnessed frequent warm winds, which ushered in major policy dividends This year's two sessions of the National People's Congress of the Communist Party of China and the Communist Party of China have provided guidance for the whole industrial chain policies of R & D, production and circulation of the pharmaceutical industry, aiming to adjust the structure and promote industrial upgrading The long-term goal of the "healthy China" strategy has officially set sail, and encouraging innovation is becoming the mainstream direction of the policy On the day after the National Day holiday, the opinions on deepening the reform of the examination and approval system and encouraging the innovation of pharmaceutical and medical devices were printed and distributed, which required all departments in all regions to earnestly implement in combination with the actual situation The opinions encourages the innovation of drugs and medical devices from six aspects, including the reform of clinical trial management, the acceleration of market review and approval, the promotion of drug innovation and the development of generic drugs Many industry research reports have said that "the pharmaceutical industry has entered a new starting point of a long cycle" Furen pharmaceutical always follows the pace of the country, adheres to the product concept of quality first, implements the quality management policy of "two concessions" of "yield yield is quality, cost is quality", and adheres to the craftsmanship spirit of making good drugs According to the data, Furen group, its controlling shareholder, invests nearly 6% of the total sales in innovation and R & D every year, and the R & D investment is three times that of domestic peer companies As Zhu Wenchen, chairman of the company, said, "an enterprise that does not innovate is not a good enterprise, and an entrepreneur that does not innovate is not a real entrepreneur Innovation is the essence of entrepreneurship, and innovation is the engine of enterprise development." In June 2013, with the strength of Beijing Furen Ruihui Biomedical Research Institute Co., Ltd and Shanghai Furen pharmaceutical R & D Co., Ltd joining in 2015, in 2017, Zhengzhou Yuance biopharmaceutical Co., Ltd officially launched the research and development and industrialization project of biomacromolecule drugs, Furen pushed its own pharmaceutical R & D plate to a new height, providing strong support for the listing platform Integrate resources to assist in making future market available It is reported that this transaction will be put into a pharmaceutical development group with strong profitability and diversified products Furen pharmaceutical will get rid of the situation that its main business is only proprietary Chinese medicine The company will increase the R & D, production and sales of chemical drugs and APIs on the basis of its main business, enrich the product structure, and effectively improve the listed company through the integration of resources with the pharmaceutical development group The comprehensive competitiveness of the company will enhance the sustainable profitability of listed companies It will basically realize the overall listing of core pharmaceutical assets of Furen group by putting into the assets of kaiyao group Injection into kaiyao group is only an important step on the board of Fu Ren In the future, we believe that we will adhere to the concept of "people's medicine is made by Fu Ren", and Fu Ren pharmaceutical industry will continue to integrate the resources of the pharmaceutical industry With the spring breeze of the pharmaceutical and health industry, we will realize the dream of "global Chinese manufacturer of generic drugs" Original title: welcome the pharmaceutical policy, warm wind, Fu Ren pharmaceutical industry, open the curtain of resource integration